Korro Bio, Inc. (KRRO) earnings
KRRO earnings moved a median of +4.37% by the close. Quarterly and annual KRRO reports and results, each read against the price at its own news timestamp. Back to the KRRO overview →
18 measured KRRO earnings events.
Where these KRRO earnings landedvs 15 measured KRRO earnings reactions
| Middle 50% of KRRO earnings reactions | -1.93% to +5.39% |
|---|---|
| Median reaction (to close) | +4.37% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 KRRO earnings events with a measured close landed between -1.93% and +5.39%; 60% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Korro Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +5.39% | |
| Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.00% | +5.39% | |
| Form 10-Q Korro Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.89% | -0.85% | |
| Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +1.89% | -0.85% | |
| Form 10-K Korro Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | +5.33% | -5.33% | |
| Form 10-Q Korro Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.72% | — | |
| Form 10-Q Korro Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | — | — | |
| Form 10-Q Korro Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.61% | +12.57% | |
| Korro Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -1.61% | +12.57% | |
| Form 10-K Korro Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | -6.18% | -3.01% | |
| Form 10-Q Korro Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.33% | -16.63% | |
| Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | -1.33% | -16.63% | |
| Form 10-Q Korro Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.11% | +5.11% | |
| Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | +1.11% | +5.11% | |
| Form 10-Q Korro Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.87% | +4.37% | |
| Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer | Press release | +0.87% | +4.37% | |
| Form 10-K Korro Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.04% | +6.65% |
Keep exploring
More KRRO: analyst actions → · SEC filings → · KRRO overview →